The role of TNFR2+ Tregs in COVID-19: An overview and a potential therapeutic strategy

被引:12
|
作者
Ahmad, Suhana [1 ]
Hatmal, Ma'mon M. [2 ]
Lambuk, Lidawani [1 ]
Al-Hatamleh, Mohammad A., I [1 ]
Alshaer, Walhan [3 ]
Mohamud, Rohimah [1 ]
机构
[1] Univ Sains Malaysia, Sch Med Sci, Dept Immunol, Kubang Kerian 16150, Kelantan, Malaysia
[2] Hashemite Univ, Fac Appl Hlth Sci, Dept Med Lab Sci, POB 330127, Zarqa 13133, Jordan
[3] Univ Jordan, Cell Therapy Ctr CTC, Amman 11942, Jordan
关键词
TNF-TNFR2; SARS-CoV-2; Immunotherapy; Immune tolerance; TUMOR-NECROSIS-FACTOR; REGULATORY T-CELLS; NF-KAPPA-B; TNF-ALPHA; RECEPTOR; IMMUNE-RESPONSE; EXPRESSION; PHENOTYPE; MACROPHAGES; SUPPRESSION;
D O I
10.1016/j.lfs.2021.120063
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
COVID-19 is a multi-faceted disease ranging from asymptomatic to severely ill condition that primarily affects the lungs and could advance to other organs as well. It's causing factor, SARS-CoV-2 is recognized to develop robust cell-mediated immunity that responsible to either control or exaggerate the infection. As an important cell subset that control immune responses and are significantly dysregulated in COVID-19, Tregs is proposed to be considered for COVID-19 management. Among its hallmark, TNFR2 is recently recognized to play important role in the function and survival of Tregs. This review gathers available TNFR2 agonists to directly target Tregs as a potential approach to overcome immune dysregulation that affect the severity in COVID-19. Furthermore, this review performs a rigid body docking of TNF-TNFR2 interaction and such interaction with TNFR2 agonist to predict the optimal targeting approach.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Can Activation of NRF2 Be a Strategy COVID-19?
    Cuadrado, Antonio
    Pajares, Marta
    Benito, Cristina
    Jimenez-Villegas, Jose
    Escoll, Maribel
    Fernandez-Gines, Raquel
    Yague, Angel J. Garcia
    Lastra, Diego
    Manda, Gina
    Rojo, Ana I.
    Dinkova-Kostova, Albena T.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2020, 41 (09) : 598 - 610
  • [42] Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview
    Khosroshahi, Leila Mohamed
    Rokni, Mohsen
    Mokhtari, Tahmineh
    Noorbakhsh, Farshid
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2021, 93
  • [43] Potential role for tissue factor in the pathogenesis of hypercoagulability associated with in COVID-19
    Bautista-Vargas, Mario
    Bonilla-Abadia, Fabio
    Canas, Carlos A.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2020, 50 (03) : 479 - 483
  • [44] COVID-19 Outbreak: An Overview
    Ciotti, Marco
    Angeletti, Silvia
    Minieri, Marilena
    Giovannetti, Marta
    Benvenuto, Domenico
    Pascarella, Stefano
    Sagnelli, Caterina
    Bianchi, Martina
    Bernardini, Sergio
    Ciccozzi, Massimo
    CHEMOTHERAPY, 2020, 64 (5-6) : 215 - 223
  • [45] Withaferin A: a potential therapeutic agent against COVID-19 infection
    Straughn, Alex R.
    Kakar, Sham S.
    JOURNAL OF OVARIAN RESEARCH, 2020, 13 (01)
  • [46] Potential therapeutic approach of intravenous immunoglobulin against COVID-19
    Kolahchi, Zahra
    Sohrabi, Hanye
    Ekrami Nasab, Sara
    Jelodari Mamaghani, Hesan
    Keyfari Alamdari, Maryam
    Rezaei, Nima
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2021, 17 (01)
  • [47] The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic
    Aigner, Ludwig
    Pietrantonio, Frank
    Bessa de Sousa, Diana Marisa
    Michael, Johanna
    Schuster, Daniela
    Reitsamer, Herbert Anton
    Zerbe, Horst
    Studnicka, Michael
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2020, 7
  • [48] Micronutrients for potential therapeutic use against COVID-19; a review
    Giovane, Richard A.
    Di Giovanni-Kinsley, Stephanie
    Keeton, Emily
    CLINICAL NUTRITION ESPEN, 2021, 46 : 9 - 13
  • [49] Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic Strategies
    Samidurai, Arun
    Das, Anindita
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (18) : 1 - 28
  • [50] Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19
    Naik, Rajashri R.
    Shakya, Ashok K.
    Aladwan, Safwan M.
    El-Tanani, Mohamed
    FRONTIERS IN PHARMACOLOGY, 2022, 13